See more : Hydro One Limited (HRNNF) Income Statement Analysis – Financial Results
Complete financial analysis of Tetra Bio-Pharma Inc. (TBP.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tetra Bio-Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ERG S.p.A. (ERG.MI) Income Statement Analysis – Financial Results
- Putprop Limited (PPR.JO) Income Statement Analysis – Financial Results
- SBF AG (CY1K.F) Income Statement Analysis – Financial Results
- Shree Cement Limited (SHREECEM.BO) Income Statement Analysis – Financial Results
- Hawks Acquisition Corp (HWKZ) Income Statement Analysis – Financial Results
Tetra Bio-Pharma Inc. (TBP.TO)
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. The company is headquartered in Orléans, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 112.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 67.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 44.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 39.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.94M | 11.65M | 6.20M | 5.96M | 2.06M | 263.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.25M | 8.77M | 7.64M | 5.66M | 4.33M | 719.17K | 473.82K | 310.23K | 153.82K | 285.96K | 377.50K | 250.98K | 298.81K | 467.53K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 603.44K | 0.00 | 106.39K | 109.71K | 40.10K | 12.09K | 115.75K | 130.80K | 8.76K | 23.20K | 48.63K | 0.00 |
| SG&A | 12.25M | 8.77M | 7.64M | 5.66M | 4.33M | 825.56K | 583.53K | 350.33K | 165.91K | 401.71K | 508.30K | 259.75K | 322.01K | 516.16K | 0.00 |
| Other Expenses | 111.95K | 34.39K | 27.48K | 113.96K | 7.20K | -106.39K | -109.71K | -40.10K | -9.70K | 0.00 | 1.04M | 164.30K | 19.11K | 12.69K | 114.28K |
| Operating Expenses | 24.30M | 20.46M | 13.86M | 11.63M | 6.40M | 982.71K | 473.82K | 310.23K | 156.21K | 401.71K | 1.55M | 424.05K | 341.13K | 528.85K | 114.28K |
| Cost & Expenses | 24.30M | 20.46M | 13.86M | 11.70M | 6.40M | 982.71K | 473.82K | 310.23K | 156.21K | 401.71K | 1.55M | 424.05K | 341.13K | 528.85K | 114.28K |
| Interest Income | 105.03K | 98.01K | 89.77K | 113.96K | 487.00 | 55.76K | 4.13K | 225.00 | 1.89K | 3.52K | 6.04K | 341.00 | 331.00 | 7.32K | 93.00 |
| Interest Expense | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.95K | 34.39K | 27.48K | 7.20K | 7.20K | 38.46K | -120.96K | -103.90K | -1.95M | -225.64K | -219.72K | -85.82K | -32.33K | -1.16M | -19.91K |
| EBITDA | -24.73M | -19.91M | -13.36M | -15.20M | -6.22M | -944.26K | -594.78K | -414.13K | -2.11M | -627.35K | -1.77M | -509.87K | -373.46K | -1.69M | -134.18K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -13,528.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -24.84M | -19.94M | -13.39M | -11.58M | -6.40M | -982.71K | -473.82K | -310.23K | -156.21K | -401.71K | -1.55M | -424.05K | -341.13K | -528.85K | -114.28K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -10,313.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -27.33M | -1.21M | -860.16K | 3.73M | -298.56K | -14.25K | -120.96K | -103.90K | -1.95M | -225.64K | -219.72K | -86.16K | -32.66K | -1.16M | -20.00K |
| Income Before Tax | -52.18M | -21.15M | -14.25M | -7.85M | -6.70M | -996.97K | -594.78K | -414.13K | -2.11M | -627.35K | -1.77M | -510.21K | -373.79K | -1.69M | -134.28K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -6,990.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.24M | 5.75M | 1.42M | 3.73M | -298.56K | -52.71K | 0.00 | 0.00 | 0.00 | -72.44K | -315.30K | -341.00 | -331.00 | -7.32K | -93.00 |
| Net Income | -53.42M | -26.90M | -15.67M | -7.57M | -6.23M | -944.26K | -594.78K | -414.13K | -2.11M | -554.91K | -1.46M | -509.87K | -373.46K | -1.69M | -134.18K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -6,741.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.12 | -0.10 | -0.08 | -0.05 | -0.06 | -0.02 | -0.01 | -0.02 | -0.08 | -0.02 | -0.08 | -0.04 | -0.05 | -0.32 | -0.04 |
| EPS Diluted | -0.12 | -0.10 | -0.08 | -0.05 | -0.06 | -0.02 | -0.01 | -0.02 | -0.08 | -0.02 | -0.08 | -0.04 | -0.05 | -0.32 | -0.04 |
| Weighted Avg Shares Out | 445.70M | 258.15M | 188.24M | 145.69M | 107.80M | 55.47M | 55.47M | 26.25M | 26.25M | 23.94M | 19.07M | 11.39M | 7.91M | 5.22M | 3.08M |
| Weighted Avg Shares Out (Dil) | 445.70M | 258.15M | 188.24M | 145.69M | 107.80M | 55.47M | 55.47M | 26.25M | 26.25M | 23.94M | 19.07M | 11.39M | 7.91M | 5.22M | 3.08M |
Source: https://incomestatements.info
Category: Stock Reports